Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−5.2206 EUR
−17.03 M EUR
0.00 EUR
5.17 M
About BIOPHYTIS
Sector
CEO
Stanislas Veillet
Headquarters
Paris
Website
Founded
2006
ISIN
FR001400OLP5
FIGI
BBG00JRQT394
Biophytis SA operates as a clinical-stage biotechnology company. It specializes in the development of therapeutics that are aimed at slowing the degenerative processes associated with aging, including severe respiratory failure in patients suffering from COVID-19. Its products include Sarconeos (BIO101), which is used to treat sarcopenic obesity and Macuneos (BIO201), which is used to treat dry age-related macular degeneration (AMD). The company was founded by Stanislas Veillet and René Lafont on September 27, 2006 and is headquartered in Paris, France.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of 0D1W is 0.2999 EUR — it has increased by 3.02% in the past 24 hours. Watch BIOPHYTIS EUR0.8 (POST CONSOLIDATION) stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on LSE exchange BIOPHYTIS EUR0.8 (POST CONSOLIDATION) stocks are traded under the ticker 0D1W.
0D1W stock has fallen by −0.03% compared to the previous week, the month change is a −13.42% fall, over the last year BIOPHYTIS EUR0.8 (POST CONSOLIDATION) has showed a −87.07% decrease.
0D1W reached its all-time high on Jan 19, 2018 with the price of 1,744.0000 EUR, and its all-time low was 0.2900 EUR and was reached on Oct 29, 2024. View more price dynamics on 0D1W chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
0D1W stock is 2.93% volatile and has beta coefficient of 1.08. Track BIOPHYTIS EUR0.8 (POST CONSOLIDATION) stock price on the chart and check out the list of the most volatile stocks — is BIOPHYTIS EUR0.8 (POST CONSOLIDATION) there?
Today BIOPHYTIS EUR0.8 (POST CONSOLIDATION) has the market capitalization of 1.58 M, it has increased by 0.03% over the last week.
Yes, you can track BIOPHYTIS EUR0.8 (POST CONSOLIDATION) financials in yearly and quarterly reports right on TradingView.
BIOPHYTIS EUR0.8 (POST CONSOLIDATION) is going to release the next earnings report on Feb 24, 2025. Keep track of upcoming events with our Earnings Calendar.
0D1W net income for the last half-year is −5.81 M EUR, while the previous report showed −9.26 M EUR of net income which accounts for 37.25% change. Track more BIOPHYTIS EUR0.8 (POST CONSOLIDATION) financial stats to get the full picture.
No, 0D1W doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, 0D1W shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade BIOPHYTIS EUR0.8 (POST CONSOLIDATION) stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So BIOPHYTIS EUR0.8 (POST CONSOLIDATION) technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating BIOPHYTIS EUR0.8 (POST CONSOLIDATION) stock shows the sell signal. See more of BIOPHYTIS EUR0.8 (POST CONSOLIDATION) technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.